lobbying_activities: 1663464

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
1663464	9d3d0114-ddd1-45b1-9924-468195ce941a	Q1	APOTEX CORP.	310973	APOTEX CORP.	2015	first_quarter	PHA	FDA proposed rule, Supplemental Applications Proposing Labeling Changes For Approved Drugs And Biological Products, Docket Number FDA-2013-N-0500, provisions relating to generic drug labeling changes; House Energy & Commerce Committees 21st Century Cures discussion draft, provisions relating to federal policies regarding the discovery, approval and manufacturing of pharmaceuticals; Federal policy relating to International Nonproprietary Names for biosimilars; Federal policy relating to the provision of brand drug products by brand manufacturers to generic manufacturers for development testing; Federal policy relating to the implementation of the Biologic Price Competition and Innovation Act, Title VII, Subtitle A, of Public Law 111-148, the Patient Protection and Affordable Care Act, and; Federal policy relating to the Implementation of Public Law 112-144, The Food and Drug Administration Safety and Innovation Act, Title 3, Fees Relating to Generic Drugs	HOUSE OF REPRESENTATIVES,SENATE		160000	0	0	2015-04-16T10:54:22.933000-04:00